Vital Therapies, Inc. (NASDAQ:VTL) has been assigned an average rating of “Hold” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $8.00.

A number of equities research analysts have recently weighed in on VTL shares. Zacks Investment Research lowered shares of Vital Therapies from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. ValuEngine raised shares of Vital Therapies from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 21st. Finally, BidaskClub raised shares of Vital Therapies from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 5th.

In other news, Director Jean Jacques Bienaime bought 10,000 shares of the firm’s stock in a transaction on Wednesday, September 13th. The stock was acquired at an average cost of $4.00 per share, with a total value of $40,000.00. Following the completion of the acquisition, the director now owns 65,119 shares of the company’s stock, valued at $260,476. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Muneer A. Satter bought 50,000 shares of the firm’s stock in a transaction on Friday, September 8th. The stock was purchased at an average cost of $3.53 per share, with a total value of $176,500.00. The disclosure for this purchase can be found here. Insiders acquired 190,000 shares of company stock valued at $737,800 over the last ninety days. Corporate insiders own 32.60% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in shares of Vital Therapies during the first quarter valued at approximately $167,000. Goldman Sachs Group Inc. raised its holdings in shares of Vital Therapies by 1.8% during the first quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock valued at $258,000 after purchasing an additional 1,157 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Vital Therapies by 11.5% during the first quarter. Bank of New York Mellon Corp now owns 88,104 shares of the company’s stock valued at $352,000 after purchasing an additional 9,120 shares during the last quarter. Susquehanna International Group LLP purchased a new position in shares of Vital Therapies during the second quarter valued at approximately $268,000. Finally, Blair William & Co. IL raised its holdings in shares of Vital Therapies by 67.2% during the second quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock valued at $289,000 after purchasing an additional 40,000 shares during the last quarter. 25.58% of the stock is owned by hedge funds and other institutional investors.

Vital Therapies (NASDAQ:VTL) last announced its earnings results on Wednesday, October 25th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. During the same quarter in the prior year, the business posted ($0.32) EPS.

TRADEMARK VIOLATION WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.watchlistnews.com/analysts-set-vital-therapies-inc-vtl-pt-at-8-00/1673989.html.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.